Letaplimab( —— )

Catalog No. M37171 CAS No. 2283356-07-8

Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	375	Get Quote
5MG	613	Get Quote
10MG	938	Get Quote
25MG	1408	Get Quote
50MG	1822	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Letaplimab
Note

Research use only, not for human use.
Brief Description

Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes.
Description

Letaplimab (IBI-188) is a humanized IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

2283356-07-8
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Miao Miao, et al. A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome. MYELODYSPLASTIC SYNDROMES-CLINICAL AND EPIDEMIOLOGICAL NOVEMBER 15, 2022.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks